Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment

Cancer Treatment Reviews

Volumn 38, Issue 8, 2012, Pages 1012-1019

  Dimopoulos, Meletios A ^a   Terpos, Evangelos ^a   Goldschmidt, Hartmut ^b,c   Alegre, Adrian ^d   Mark, Tomer ^e   Niesvizky, Ruben ^e  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Dosing; Efficacy; Lenalidomide; Multiple myeloma; Renal impairment; Safety

Indexed keywords

BORTEZOMIB; CREATININE; DEXAMETHASONE; LENALIDOMIDE; THALIDOMIDE;

ACUTE KIDNEY FAILURE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOSE KIDNEY FUNCTION RELATION; DRUG ABSORPTION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG MONITORING; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HIGH RISK POPULATION; HUMAN; INFECTION; KIDNEY DISEASE; KIDNEY FUNCTION; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PLASMAPHERESIS; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; REVIEW; RISK REDUCTION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DEXAMETHASONE; HUMANS; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; THALIDOMIDE;

EID: 84867141947     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.02.009     Document Type: Review

References (50)

1. Abbott K.C., Agodoa L.Y. Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival. Clin Nephrol 2001, 56:207-210.
2. Dimopoulos M.A., Terpos E., Chanan-Khan A., et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010, 28:4976-4984.
3. Dimopoulos M.A., Kastritis E., Rosinol L., Bladé J., Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 2008, 22:1485-1493.
4. Santostefano M., Zanchelli F., Zaccaria A., Poletti G., Fusaroli M. The ultrastructural basis of renal pathology in monoclonal gammopathies. J Nephrol 2005, 18:659-675.
5. Keeling J., Herrera G.A. The mesangium as a target for glomerulopathic light and heavy chains: pathogenic considerations in light and heavy chain-mediated glomerular damage. Contrib Nephrol 2007, 153:116-134.
6. Knudsen L.M., Hjorth M., Hippe E. Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000, 65:175-181.
7. Augustson B.M., Begum G., Dunn J.A., et al. Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005, 23:9219-9226.
8. Dimopoulos M.A., Kastritis E., Roussou M., et al. Renal impairment is not an independent adverse prognostic factor in multiple myeloma patients who are treated upfront with novel agent-based regimens. Blood (ASH Annual Meeting Abstracts) 2010, 116. [abstract 3033].
9. Roussou M., Kastritis E., Christoulas D., et al. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 2010, 34:1395-1397.
10. Dimopoulos M., Alegre A., Stadtmauer E.A., et al. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 2010, 116:3807-3814.
11. Dimopoulos M.A., Christoulas D., Roussou M., et al. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol 2010, 85:1-5.
12. Levey A.S., Bosch J.P., Breyer Lewis J., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999, 130:461-470.
13. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 6:31-41.
14. Pierrat A., Gravier E., Saunders C., et al. Predicting GFR in children and adults: a comparison of the Cockcroft-Gault, Schwartz, and Modification of Diet and Renal Disease formulas. Kidney Int 2003, 64:1425-1436.
15. Goldberg T.H., Finkelstein M.S. Difficulties in estimating glomerular filtration rate in the elderly. Arch Intern Med 1987, 147:1430-1433.
16. Niesvizky R., Naib T., Christos P.J., et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol 2007, 138:640-643.
17. Levey A.S., Eckardt K.U., Tsukamoto Y., et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005, 67:2089-2100.
18. Bellomo R., Ronco C., Kellum J.A., et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004, 8:R204-R212.
19. Mehta R.L., Kellum J.A., Shah S.V., et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007, 11:R31.
20. Dimopoulos M.A., Roussou M., Gavriatopoulou M., et al. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. Clin Lymphoma Myeloma 2009, 9:302-306.
21. Dimopoulos M.A., Richardson P.G., Schlag R., et al. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 2009, 27:6086-6093.
22. Ludwig P., Adam Z., Greil R., et al. Recovery of renal impairment by bortezomib-doxorubicin-dexamethasone (BDD) in multiple myeloma (MM) patients with acute renal failure. Results from an ongoing phase II study. Haematologica 2008, 93(Suppl. 1):S117. [abstract 0439].
23. Hutchison C.A., Bradwell A.R., Cook M., et al. Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009, 4:745-754.
24. Kastritis E., Anagnostopoulos A., Roussou M., et al. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 2007, 92:546-549.
25. Mitsiades N., Mitsiades C.S., Poulaki V., et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99:4525-4530.
26. Verhelle D., Corral L.G., Wong K., et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007, 67:746-755.
27. Escoubet-Lozach L., Lin I.L., Jensen-Pergakes K., et al. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009, 69:7347-7356.
28. Gandhi A.K., Kang J., Capone L., et al. Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function. Curr Cancer Drug Targets 2010, 10:155-167.
29. Chang D.H., Liu N., Klimek V., et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006, 108:618-621.
30. Noonan K.A., Ferguson A., Huff C.A., et al. The immunomodulatory role of lenalidomide on Prevnar® responses in patients with relapsed multiple myeloma: a comprehensive analysis of the immune response. Blood (ASH Annual Meeting Abstracts) 2008, 112. [abstract 2772].
31. Wu L., Adams M., Carter T., et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008, 14:4650-4657.
32. Baz R., Dimopoulos M., Richardson P., et al. Lenalidomide-based therapy leads to improvement of humoral immune system in relapsed or refractory multiple myeloma patients who respond to the therapy. Haematologica 2009, 94(Suppl. 2):159. [abstract 0395].
33. Lioznov M., El-Cheikh J., Hoffmann F., et al. Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. Bone Marrow Transplant 2010, 45:349-353.
34. Chanan-Khan A.A., Cheson B.D. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008, 26:1544-1552.
35. Dimopoulos M., Spencer A., Attal M., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357:2123-2132.
36. Weber D.M., Chen C., Niesvizky R., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007, 357:2133-2142.
37. Dimopoulos M.A., Chen C., Spencer A., et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009, 23:2147-2152.
38. Klein U., Neben K., Hielscher T., et al. Lenalidomide in combination with dexamethasone: effective regimen in patients with relapsed or refractory multiple myeloma complicated by renal impairment. Ann Hematol 2011, 90:429-439.
39. Rajkumar S.V., Jacobus S., Callander N.S., et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010, 11:29-37.
40. Niesvizky R., Jayabalan D.S., Christos P.J., et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008, 111:1101-1109.
41. Richardson P.G., Weller E., Lonial S., et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010, 116:679-686.
42. REVLIMID (lenalidomide capsules). Prescribing information, October 2010. Celgene Corporation, Summit, NJ, USA. Available from: http://www.revlimid.com/pdf/REVLIMID_PI.pdf.
43. Chen N., Lau H., Kong L., et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007, 47:1466-1475.
44. Reece D.E., Masih-Khan E., Chen C., et al. Use of lenalidomide (Revlimid®)±corticosteroids in relapsed/refractory multiple myeloma patients with elevated baseline serum creatinine levels. Blood (ASH Annual Meeting Abstracts) 2006, 108. [abstract 3548].
45. Harvey RD, Jacobus SJ, Rajkumar SV, et al. Renal function measures improve on lenalidomide and dexamethasone and compete with patient characteristics to predict lenalidomide dose density and hematologic toxicity: an E4A03 analysis. Blood (ASH Annual Meeting Abstracts) 2011; 118 [abstract 1882].
46. de la Rubia J., Roig M., Ibáñez A., et al. Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study. Eur J Haematol 2010, 85:363-365.
47. Kneppers E., Lokhorst H.M., Eeltink C.M., et al. Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program. Clin Lymphoma Myeloma Leuk 2010, 10:138-143.
48. Alegre A., Aguado B., Giraldo P., et al. Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in Advanced Patients. Int J Hematol 2011, 93:351-360.
49. Quach H., Fernyhough L., Henderson R., et al. Lower-dose lenalidomide and dexamethasone reduces toxicity without compromising efficacy in patients with relapsed/refractory myeloma, who are aged ≥60years or have renal impairment: planned interim results of a prospective multicentre phase II trial. Blood (ASH Annual Meeting Abstracts) 2010, 116. [abstract 1961].
50. Ludwig H., Spicka I., Thaler J., et al. Lenalidomide-dexamethasone (LD) as treatment of acute cast nephropathy-induced renal failure (ARF) in multiple myeloma (MM). A phase II study. Haematologica 2011, 96(Suppl. 2):127-128. [abstract 0306].